What is the current valuation of the US Ophthalmic Topical Therapeutics Market?

The market valuation was 3.59 USD Billion in 2024. Read More

What is the projected market size for the US Ophthalmic Topical Therapeutics Market by 2035?

The market is expected to reach 7.23 USD Billion by 2035. Read More

What is the expected CAGR for the US Ophthalmic Topical Therapeutics Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 6.57%. Read More

Which companies are considered key players in the US Ophthalmic Topical Therapeutics Market?

Key players include Allergan, Bausch + Lomb, Regeneron Pharmaceuticals, and Novartis. Read More

What segment had the highest valuation in the US Ophthalmic Topical Therapeutics Market in 2024?

The Antiglaucoma segment had the highest valuation at 1.0 USD Billion. Read More

How does the valuation of the Dry Eye Disease segment compare to others in 2024?

The Dry Eye Disease segment was valued at 1.2 USD Billion, making it one of the leading segments. Read More

What are the projected valuations for the Antibiotic segment by 2035?

The Antibiotic segment is projected to reach 1.5 USD Billion by 2035. Read More

Which end user segment is expected to show the highest growth by 2035?

The Pharmacies segment is projected to grow to 2.0 USD Billion by 2035. Read More

What formulation type is anticipated to have the largest market share in 2035?

Solutions are expected to dominate with a projected valuation of 2.4 USD Billion by 2035. Read More

What therapeutic area is projected to experience significant growth in the US Ophthalmic Topical Therapeutics Market?

The Glaucoma therapeutic area is projected to grow to 1.8 USD Billion by 2035. Read More

US Ophthalmic Topical Therapeutics Market

ID: MRFR/HC/18447-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

US Ophthalmic Topical Therapeutics Market Research Report: By Product Type (Artificial Tears, Anti-allergy, Antibiotic Drops, Anti-Inflammatory, Antiglaucoma, Others), By Disease Type (Dry Eye, Eye Allergy, Glaucoma, Eye Infection, Retinal Disorders, Uveitis, Others), By Dosage Form (Eye Drops, Gels, Ointments, Others) and By Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies, Others) - Growth & Industry Forecast 2025 To 2035

US Ophthalmic Topical Therapeutics Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Anti-inflammatory
  2. 4.1.2 Antibiotic
  3. 4.1.3 Antiviral
  4. 4.1.4 Antiglaucoma
  5. 4.1.5 Lubricants
2. 4.2 Healthcare, BY Formulation Type (USD Billion)
  1. 4.2.1 Solutions
  2. 4.2.2 Suspensions
  3. 4.2.3 Ointments
  4. 4.2.4 Gels
  5. 4.2.5 Emulsions
3. 4.3 Healthcare, BY Route of Administration (USD Billion)
  1. 4.3.1 Topical
  2. 4.3.2 Intravitreal
  3. 4.3.3 Subconjunctival
  4. 4.3.4 Periocular
  5. 4.3.5 Systemic
4. 4.4 Healthcare, BY Therapeutic Area (USD Billion)
  1. 4.4.1 Glaucoma
  2. 4.4.2 Dry Eye Disease
  3. 4.4.3 Infectious Diseases
  4. 4.4.4 Allergic Conjunctivitis
  5. 4.4.5 Retinal Disorders
5. 4.5 Healthcare, BY End User (USD Billion)
  1. 4.5.1 Hospitals
  2. 4.5.2 Ophthalmology Clinics
  3. 4.5.3 Homecare Settings
  4. 4.5.4 Pharmacies
  5. 4.5.5 Research Institutions
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Allergan (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bausch + Lomb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Regeneron Pharmaceuticals (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Santen Pharmaceutical (JP)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Aerie Pharmaceuticals (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Horizon Therapeutics (IE)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Ocular Therapeutix (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 EyePoint Pharmaceuticals (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY FORMULATION TYPE
4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 US MARKET ANALYSIS BY THERAPEUTIC AREA
6. 6.6 US MARKET ANALYSIS BY END USER
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
15. 6.15 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
17. 6.17 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
19. 6.19 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
21. 6.21 HEALTHCARE, BY END USER, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  2. 7.2.2 BY FORMULATION TYPE, 2026-2035 (USD Billion)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Billion)
  4. 7.2.4 BY THERAPEUTIC AREA, 2026-2035 (USD Billion)
  5. 7.2.5 BY END USER, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

Anti-inflammatory
Antibiotic
Antiviral
Antiglaucoma
Lubricants

Healthcare By Formulation Type (USD Billion, 2026-2035)

Solutions
Suspensions
Ointments
Gels
Emulsions

Healthcare By Route of Administration (USD Billion, 2026-2035)

Topical
Intravitreal
Subconjunctival
Periocular
Systemic

Healthcare By Therapeutic Area (USD Billion, 2026-2035)

Glaucoma
Dry Eye Disease
Infectious Diseases
Allergic Conjunctivitis
Retinal Disorders

Healthcare By End User (USD Billion, 2026-2035)

Hospitals
Ophthalmology Clinics
Homecare Settings
Pharmacies
Research Institutions

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”